Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Received | |||
N/A | enzalutamide | Genito-urinary cancer (prostate cancer) | Open for Stakeholder Input | |||
TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Active | |||
TBC | avapritinib | Advanced Systemic Mastocytosis | Active | |||
Alecensaro | alectinib | ALK-positive NSCLC | Active | |||
Adcetris | Brentuximab vedotin | Hodgkin lymphoma | Active | |||
Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Active | |||
TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Active | |||
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active | |||
TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Active |